DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth (NASDAQ: DRIO) announced a new agreement with a major Arizona health insurer through its Amwell partnership, making its cardiometabolic digital health solution available to the insurer's ASO employer clients, representing access to hundreds of thousands of covered lives.
The deal supports Dario's channel-led, capital-efficient growth model, expanding recurring revenue opportunities and leveraging a network reaching over 116 million covered lives, with an employer ROI of up to 5x reported in a Sanofi-funded study.
DarioHealth (NASDAQ: DRIO) announced that one of the 5 largest U.S. health insurers extended its agreement and added Dario’s AI-powered hypertension solution after success with its behavioral health program.
The expanded cardiometabolic rollout may roughly triple revenue opportunity from this client, with contributions expected in 2026 and greater impact from 2027. This is the third health plan to expand beyond an initial condition, supporting Dario’s multi-condition strategy. Dario now serves 12 health plans, including 3 national carriers, across 6 chronic condition solutions using Beluga-enabled care delivery.
DarioHealth (NASDAQ: DRIO) appointed former Humana Senior Vice President and Chief Compliance Officer Sean O'Reilly to its Advisory Board.
The move is intended to strengthen compliance, regulatory and payer expertise as Dario advances its AI-enabled digital health platform and channel partner-led growth with health plans, employers and providers.
Dario (NASDAQ: DRIO) announced a Collaborative Services Agreement with Beluga Health to deliver provider-backed, digitally enabled chronic care across all 50 states.
The integrated platform combines coaching, AI triage and Beluga’s physician network to monitor, detect and treat conditions including diabetes, hypertension, obesity, behavioral health and musculoskeletal issues, using one vendor relationship.
The partnership targets health plans, health systems, employers and public programs, with evidence from a JMIR study showing Dario users had 23% lower hospitalization rates and 26% lower total charges than matched usual-care patients.
DarioHealth (NASDAQ: DRIO) reported four new studies at the American Diabetes Association Scientific Sessions showing clinical and economic signals from its digital cardiometabolic platform.
Results included 0.23 fewer hospitalizations PPPY, 6.4%–14.3% 12‑month weight loss, and 44.8% of high‑risk diabetes users achieving ≥1% eA1c reduction.
DarioHealth (NASDAQ: DRIO) announced that Solera Health has expanded Dario's digital offerings to include a broader hypertension program, now covering pre-hypertensive members through Stage 2 hypertension.
This more than doubles Dario's addressable market within Solera's network, tying revenue to engagement, longitudinal outcomes and recurring, year-long member experiences.
DarioHealth (NASDAQ: DRIO) reported first quarter 2026 revenue of $5.6 million, up 6.7% sequentially but below $6.8 million a year earlier, mainly due to non-recurring prior pharma revenue. GAAP gross margin was 57%; operating expenses fell to $10.5 million (down 21% YoY), cutting operating loss to $7.3 million. Net loss was $8.2 million. Cash and short-term deposits totaled $20 million, with $6 million net cash used in operations. Channel partnerships provide access to over 116 million covered lives, with a new contract in progress that could raise reach above 175 million. DarioHealth added 10 new accounts and reported a $127 million pipeline across 241 active opportunities.
DarioHealth (Nasdaq: DRIO) will report first quarter 2026 financial results for the period ended March 31, 2026 and will host a live conference call and webcast on Wednesday, May 13, 2026 at 8:30 a.m. ET, before the market opens.
Executives Erez Raphael, Steven Nelson, and Chen Franco-Yehuda will host. A replay will be available through Wednesday, May 27, 2026.
DarioHealth (NASDAQ: DRIO) announced a peer‑reviewed JMIR Formative Research publication (April 20, 2026) reporting statistically significant improvements in workplace functioning from its digital behavioral health program.
Among users, focus and task completion improved within six weeks (n=1,254 for concentration), with larger gains by weeks 6–10; comparable gains seen for procrastination (n=1,004) and mistakes at work (n=167).
DarioHealth (NASDAQ: DRIO) appointed veteran healthcare executive John R. Palumbo to its Board of Directors effective April 13, 2026. Palumbo brings more than 40 years of healthcare operating experience, board service, and relationships across payers, health systems and provider services to support accelerated commercial scaling.
The appointment aligns board composition with a partner-led, capital-efficient go-to-market strategy and aims to expand channel partnerships and commercial momentum.